County–level variation in preterm birth rates

JAMA Network Open

2023-12-08

(Press-News.org) About The Study: In this analysis of U.S. county-level preterm and early preterm birth rates, substantial geographic disparities were observed, which were associated with place-based social disadvantage. Stability in aggregated rates of preterm birth at the national level masked increases in nearly 1 in 6 counties between 2007 and 2019.

Authors: Sadiya S. Khan, M.D.,M.S., of the Northwestern University Feinberg School of Medicine in Chicago, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2023.46864)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.46864?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=120823

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

END

ELSE PRESS RELEASES FROM THIS DATE:

T cells tackle new 'Pirola' SARS-CoV-2 variant

2023-12-08

LA JOLLA, CA—In August, researchers detected a new SARS-CoV-2 "variant of concern" in patients in Israel and Denmark. Since then, this variant, dubbed BA.2.86 or "Pirola," has made its way around the globe. The Pirola variant has raised alarms because it is highly mutated. In fact, Pirola is as mutated as the Omicron variant was, compared with the early SARS-CoV-2 variant included in the original vaccinations. As Pirola spreads, researchers at La Jolla Institute for Immunology (LJI) are investigating whether COVID-19 vaccines (or previous ...

MIT engineers design a robotic replica of the heart’s right chamber

2023-12-08

MIT engineers have developed a robotic replica of the heart’s right ventricle, which mimics the beating and blood-pumping action of live hearts. The robo-ventricle combines real heart tissue with synthetic, balloon-like artificial muscles that enable scientists to control the ventricle’s contractions while observing how its natural valves and other intricate structures function. The artificial ventricle can be tuned to mimic healthy and diseased states. The team manipulated the model to simulate conditions of right ventricular dysfunction, ...

New cause of diabetes discovered, offering potential target for new classes of drugs to treat the disease

2023-12-08

Dec. 8, 2023 Contact: Bill Lubinger 216.368.4443 william.lubinger@case.edu Ansley Kelm 678-313-6525 Ansley.Kelm@UHhospitals.org CLEVELAND—Researchers at Case Western Reserve University and University Hospitals have identified an enzyme that blocks insulin produced in the body—a discovery that could provide a new target to treat diabetes. Their study, published Dec. 5 in the journal Cell, focuses on nitric oxide, a compound that dilates blood vessels, improves memory, fights infection and stimulates the release of hormones, among ...

MD Anderson and Rigel Pharmaceuticals announce strategic alliance to advance olutasidenib in AML and other cancers

2023-12-08

HOUSTON and SOUTH SAN FRANCISCO, Calif. ― The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia (AML) and other hematologic cancers. The alliance brings together MD Anderson’s clinical research expertise with Rigel’s differentiated targeted molecule. Under the strategic collaboration, Rigel and MD Anderson will evaluate the potential of olutasidenib to treat newly diagnosed and relapsed ...

New insights into Zebra mussel attachment fibers offer potential solutions to combat invasive species, develop sustainable materials

2023-12-08

A recent study from researchers in Canada and Germany has revealed that an unlikely event, occurring over 12 million years ago played an important role in shaping one of Canada’s most damaging invasive species. Zebra and quagga mussels, belonging to the Dreissenid family, are widespread freshwater invasive species throughout North America that present a significant danger to native ecosystems by competing for resources. Using a fibrous anchor called a byssus, Dreissenid mussels contribute to biofouling on surfaces and obstruct intake structures in power stations and water treatment plants. “This new study, which looks into the way these mussels stick to surfaces, may help improve ...

A micro-ring resonator with big potential

2023-12-08

EPFL researchers have developed a hybrid device that significantly improves existing, ubiquitous laser technology. The team at EPFL’s Photonic Systems Laboratory (PHOSL) has developed a chip-scale laser source that enhances the performance of semiconductor lasers while enabling the generation of shorter wavelengths. This pioneering work, led by Professor Camille Brès and postdoctoral researcher Marco Clementi from EPFL’s School of Engineering represents a significant advance in the field of photonics, with implications for telecommunications, metrology, and other high-precision applications. The ...

Skipping adjuvant radiotherapy may not impact risk of recurrence or progression in patients with low-risk DCIS

2023-12-08

SAN ANTONIO – Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023. “Nearly all women with DCIS—a noninvasive form of breast cancer—will have their cancer successfully removed, but some women will have a high risk of the disease returning or progressing to invasive breast cancer,” said Seema A. Khan, MD, a professor of surgery and the Bluhm Family ...

Some breast cancer survivors may safely de-escalate mammography three years after surgery

2023-12-08

Women 50 or older who de-escalated to less-frequent mammography three years after curative surgery for early-stage breast cancer had similar outcomes to women who received annual mammography, according to results from the Mammo-50 trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023. Both U.S. and U.K. guidelines recommend annual breast cancer screening following surgery to remove early-stage breast cancer; in the U.S., annual mammography is recommended indefinitely, and in the U.K., it is recommended for five years, followed by screening every three years for patients 50 years and older. However, the optimal screening schedule has yet to ...

Potentially targetable fusion RNAs may be more common in metastatic breast cancer than previously realized

2023-12-08

SAN ANTONIO – Comprehensive profiling of fusion RNAs present in a large cohort of metastatic breast tumors revealed unique fusion mutations that may be therapeutically targetable, according to results presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023. Fusion mutations occur when a portion of one gene becomes fused to a portion of another, which can create gene products with new functions. They are common in cancer types that are characterized by genomic rearrangements and structural damage to the DNA, including breast cancer. “Fusion RNAs may serve as ...

Study reveals insights into tacking diabetic kidney disease - with a side order of how anti-obesity drugs work

2023-12-08

Data from Australian researchers could partly explain why a trial of a new drug for diabetes, was recently halted because it was found to be so effective. Importantly, the data also reveals how anti-obesity drugs like Ozempic, actually work, which to date have been a mystery. In early November the FLOW trial of the drug semaglutide on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease was halted ahead of schedule because of the drug’s efficacy. Part of the rationale for the cessation of the trial could be explained by ...

County–level variation in preterm birth rates

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: